Association between Elevated Lipoprotein(a) and Cardiovascular Events and Mortality in a Nationally Representative Sample of US Medicare, Medicaid, and Commercial Enrollees with ASCVD
Abstract Body (Do not enter title and authors here): Background: Elevated lipoprotein(a) [Lp(a)] is an independent and causal risk driver for atherosclerotic cardiovascular disease (ASCVD). Few patients with ASCVD receive Lp(a) screening and real-world data assessing the association between elevated Lp(a) and risk of cardiovascular (CV) events and mortality is limited. Objectives: To examine the association of elevated Lp(a) and risk of CV events and death in an ASCVD population using large US health claims databases. Methods: Patients with ASCVD were pooled from US Medicare, commercial, and Medicaid health plans from 2017 to 2022. Lp(a) levels were linked at the patient level from HealthVerity Lab Data and categorized as: <30 mg/dL (<75 nmol/L), ≥30-<50 mg/dL (>75-<125 nmol/L), ≥50-<70 mg/dL (>125-<175 nmol/L), ≥70-<90 mg/dL (≥175-<225 nmol/L) and ≥90 mg/dL (≥225 nmol/L). Patients were followed from the 1st ASCVD diagnosis (index) to insurance plan disenrollment, death, or end of study. Cox regression, adjusted for age, sex, race, insurance, comorbidities, LDL-C, and other risk factors, measured the association between Lp(a) levels and risk of CV events and death. Results: Of 28.8 million ASCVD patients, 180,240 (0.6%) had Lp(a) levels: mean(±SD) age 68.6±1 years, 50.1% male, 5.9% Black, 2.8% Hispanic, 2.1% Asian, 72.8% Medicare, 21.8% commercial, and 5.4% Medicaid. Mean follow-up was 3.7 years; 23.3% and 15.7% had Lp(a) ≥50mg/dL [≥125 nmol/L] and ≥70 mg/dL (≥175 nmol/L), respectively. Black patients had highest median Lp(a) (50 mg/dL/111 nmol/L), followed by Asian (13.5 mg/dL/35.5 nmol/L), White (13 mg/dL/32 nmol/L), and Hispanic (11.5 mg/dL/29 nmol/L) patients. Lp(a) levels of ≥30-<50 mg/dL, ≥50-<70 mg/dL, ≥70-<90 mg/dL, and ≥90 mg/dL were associated with 7%, 10%, 16%, and 26% greater risks of CV events vs. <30 mg/dL (p-values <0.0001; cumulative incidence reported in Figure 1). All-cause mortality risk was also greater for those with Lp(a) ≥90 mg/dL vs. <30 mg/dL: hazard ratio (HR)=1.11, p=0.003. Similar trends persisted for patients with LDL-C ≤70 mg/dL. Conclusion: In this national-scale real-world cohort of patients with ASCVD, Lp(a) testing is infrequent and elevated Lp(a) levels were significantly associated with a greater risk of CV events and mortality.
Hu, Xingdi
( Novartis
, East Hanover
, New Jersey
, United States
)
Lozama, Tony
( Novartis
, East Hanover
, New Jersey
, United States
)
Petrilla, Allison
( Inovalon
, Bowie
, Maryland
, United States
)
Agatep, Barnabie
( Inovalon
, Bowie
, Maryland
, United States
)
Mcmorrow, Donna
( Inovalon
, Bowie
, Maryland
, United States
)
Mohammadi, Iman
( Inovalon
, Bowie
, Maryland
, United States
)
Reisman, Lonny
( HealthReveal
, Glen Head
, New York
, United States
)
Wong, Nathan
( University of California UC
, Irvine
, California
, United States
)
Author Disclosures:
Xingdi Hu:DO have relevant financial relationships
;
Employee:Novartis Pharmaceuticals Corporation:Active (exists now)
| Tony Lozama:DO have relevant financial relationships
;
Employee:Novartis:Active (exists now)
| Allison Petrilla:DO have relevant financial relationships
;
Consultant:Novartis:Active (exists now)
; Employee:Inovalon:Active (exists now)
| Barnabie Agatep:DO NOT have relevant financial relationships
| Donna McMorrow:DO have relevant financial relationships
;
Consultant:Novartis Pharmaceuticals Corporation:Active (exists now)
| Iman Mohammadi:DO NOT have relevant financial relationships
| Lonny Reisman:DO NOT have relevant financial relationships
| Nathan Wong:No Answer
